Clin2
NCT06144957Worth exploringEnrolling by invitation

SLC13A5 deficiency natural history study (US only)

Citrate Transporter DeficiencyEpilepsyRare DiseasesMovement DisordersGenetic DisorderSLC13A5 DeficiencyEIEE25Kohlschutter-Tonz Syndrome (Non-ROGDI)

Part of Brain & nervous system, Genetic & congenital clinical trials.

This study follows people with SLC13A5 deficiency (a rare genetic condition that affects brain development) to learn more about the disease over time. It collects health information, assessments, and samples to help understand the condition and plan future treatments.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
17 people
Ages
Any age
Study type
Observational

Who can take part

  • You or your child must have a suspected or confirmed diagnosis of SLC13A5 deficiency (a rare genetic condition affecting brain development).
  • Genetic testing must show changes in both copies of the SLC13A5 gene, but certain unclear changes may still be acceptable if your doctor and the study team agree.
  • You must be willing to share medical information, take part in assessments, and provide blood or other samples for research.
  • You cannot have another confirmed genetic or neurological disorder that could cause similar symptoms.
  • Traveling to a study site in the US once a year is preferred but not required.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04681781Enrolling by invitation
Remote study of SLC13A5 deficiency history

This study follows people with SLC13A5 deficiency to better understand how the condition changes over time, using surveys and clinical check-ins done remotely. If you (or your child) have this genetic condition, it may help researchers learn what symptoms to expect and how to track them.

Palo Alto, California
NCT07102524Recruiting· Phase 1/Phase 2
Gene therapy for SLC13A5 citrate transporter disorder

This trial tests a new gene therapy (TSHA-105) given through a spinal tap to treat SLC13A5 citrate transporter disorder, a genetic condition that affects the brain and body. The goal is to see if it can help improve symptoms by delivering a working copy of the gene.

Dallas, Texas
NCT05600946Recruiting
Study of body differences in creatine transporter deficiency

This study looks at physical and body features in people with creatine transporter deficiency caused by a specific gene change (SLC6A8). It may help doctors better understand the condition and how it shows up, which can improve future care.

Bethesda, Maryland
NCT07531511Recruiting
Understanding SLC6A1 Genetic Disorder in Children

This study tracks how children with SLC6A1 genetic mutations develop over time. Researchers will collect information about seizures, development, and daily functioning to better understand the condition and help guide future treatments.

New York, New York
NCT00029965Recruiting
Understanding rare storage diseases over time

This study follows people with rare genetic conditions (GM1, GM2, sialidosis, or galactosialidosis) that affect how the body breaks down certain substances in cells. Researchers track how these diseases progress to better understand them and potentially help future patients.

Bethesda, Maryland
NCT03758521Recruiting
Natural history study of SSADH deficiency in children and adults

This study tracks how SSADH deficiency (a genetic condition) affects health over time. There is no new drug being tested; instead, researchers collect medical history and perform certain optional scans/tests that can help describe disease patterns and future treatment needs.

Boston, Massachusetts

Hear when a new Epilepsy trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.